MYMunevver Irem Kok Yilmaz

Munevver Irem Kok Yilmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Munevver Irem Kok Yilmaz has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort

    by Emine Merve Savaş, Nurdan Kokturk, Ahmet Alparslan Ceran, Şeyma Yıldız, Münevver İrem Kök Yılmaz, Başak Bostankolu Değirmenci, Zeynep Arzu Yeğin, Gonca Erbaş, Özlem Güzel Tunçcan, Aysun Sarıer, et al.

    Background/Objectives: Chronic graft-versus-host disease (cGVHD) remains a significant complication after allogeneic stem cell transplantation. Bronchiolitis obliterans syndrome (BOS), the best characterized form of pulmonary cGVHD, represents its most severe and therapeutically challenging manifestation and is associated with poor long-term outcomes. However, data on treatment responses and survival remain limited. Methods: We performed a retrospective, single-center study to characterize the clinical features, treatment responses, and survival outcomes of patients with BOS following allo-HSCT. Results: Between January 2003 and December 2023, 28 (4.1%) of 678 transplanted patients met the National Institutes of Health (NIH) diagnostic criteria for BOS with lung scores of 2–3. The median age was 26 years (21–51), and 67.9% were male. The median time from transplantation to BOS diagnosis was 20.9 months (11.2–45.9). Median forced expiratory volume in one second (FEV1) declined from 97.5% at transplantation to 47.5% at BOS diagnosis, while median diffusing capacity for carbon monoxide (DLCO) decreased from 72% to 35% of predicted.The best observed response was partial response (PR). The overall first-line steroid-based response rate was 14.3%. In second- and subsequent-line settings, PR rates were 25% with ibrutinib, 25% with extracorporeal photopheresis, 33.3% with ruxolitinib, and 20% with mesenchymal stem cell therapy, while no responses were observed with imatinib. Median overall survival from transplantation was 90.9 months (48.4–133.5), whereas median survival from BOS diagnosis was 27.2 months (17.4–156.9). Survival after BOS diagnosis was significantly longer in patients with a prior history of acute GVHD (79.7 vs. 25.7 months; p = 0.026) and in those with concomitant extrapulmonary cGVHD compared with isolated BOS (79.7 vs. 7.6 months; p = 0.001). Conclusions: Treatment responses in stage 2–3 BOS were limited, and survival remained very poor, highlighting the importance of earlier recognition and more effective therapies before fibrotic progression.

  • Open Access

    Peritransplantation Acute Kidney Injury Has a Considerable Impact on Early Complications and Prognosis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

    by Şeyma Yıldız, Emine Merve Savaş, Fatma Pınar Cihan, İlayda Aydın, Münevver İrEm Kök, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin

    Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a curative treatment modality for a variety of hematological disorders. As baseline renal function is considered to have an essential role in the course of alloHSCT, it has been incorporated into pretransplantation scoring systems such as Sorror’s comorbidity index. The objective of this study was to assess the predictive factors that may influence the development of posttransplantation acute kidney injury (AKI), in accordance with the evaluation of the potential impact of AKI on transplantation outcome. Medical records of 434 alloHSCT recipients (median age: 44 [18–72] years; male/female: 259/175) were retrospectively reviewed. AKI was observed in a total of 316 patients (72.8%) in the first 100 days after alloHSCT. BK virus‐associated cystitis (HR: 0.412, 95% CI: 0.193–0.882; p = 0.022), sepsis (HR: 2.329, 95% CI: 1.251–4.337; p = 0.008), and infused CD34 + cell count (HR: 1.698, 95% CI: 1.186–2.430; p = 0.004) were identified as independent predictive factors for the development of posttransplantation AKI. The probability of overall survival (OS) was substantially higher in Stage I AKI compared to Stage II/III ( p = 0.03). Patients who had a higher eGFR on Day +30 had improved survival rates ( p = 0.005). AKI may represent a frequent cause of morbidity in the early posttransplantation course. Considering its multifactorial etiology, management of potential predisposing issues may help to prevent associated complications and improve transplantation outcomes.

  • Treatment Outcomes of Elderly Patients with Mantle Cell Lymphoma: A Multi-center Real-World Data

    by Ebru Kilic Gunes, Filiz Yavasoglu, Selin Kucukyurt, Fatma Aykas, Sureyya Yigit Kaya, Munevver Irem Kok Yilmaz, Murat Yildirim, Neslihan Andic, Ahmet Kursad Gunes, Volkan Karakus, et al.

    Mantle Cell Lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma (NHL), accounting for 5–7% of all lymphomas. Currently, there is no standardized treatment option for older patients (> 65 years), and optimizing MCL treatment in this group remains a significant clinical challenge. In this multicenter retrospective study, we aimed to evaluate the outcomes of first-line treatments, overall survival (OS), progression-free survival (PFS), and factors influencing survival in patients aged 65 years and older diagnosed with MCL. Patients aged ≥ 65 years diagnosed with MCL between November 2016 and January 2024 in six centers were included in this study. A total of 77 patients were included in the study, with 60 males (77.9%) and 17 females (22.1%). The median age was 71 years (range: 65–89). At diagnosis, 96.1% of patients had Stage III-IV disease, and 36.4% had an ECOG performance score of 2–3. Based on the MIPI-c score, 48% of patients had high-risk disease. As induction chemotherapy, 44.2% received R-CHOP, 13% received RB, 13% received R-CVP, and 29.8% received alternating R-CHOP/R-DHA-platinum. Additionally, 19.5% of patients underwent ASCT, and 28.6% received Rituximab maintenance after induction therapy or ASCT. The overall response rate (ORR) was 71.4%. After a median follow-up of 32 months, the median PFS was 18 months, and the median OS was 42 months. In multivariate analysis, independent risk factors for inferior PFS were LDH > ULN (HR: 2.09, 95% CI: 1.05–4.16, p = 0.035), Ki67 ≥ 30% (HR: 2.90, 95% CI: 1.38–6.10, p = 0.005), blastoid variant (HR: 1.86, 95% CI: 1.09–5.12, p = 0.040), and maintenance treatment (HR: 0.31, 95% CI: 0.12–0.75, p = 0.010). Independent risk factors for inferior OS were the maintenance treatment (HR: 0.29, 95% CI: 0.09–0.94, p = 0.040) and POD24 (HR: 2.04, 95% CI: 1.06–4.19, p = 0.044). There remains no universally accepted standard treatment for older MCL patients, and the disease remains incurable with current treatment modalities. However, advancements in targeted therapies and the optimization of maintenance strategies hold promise for improving survival in older and unfit patients. Future studies focusing on incorporating targeted therapies into first-line treatment and identifying high-risk factors that influence survival will be crucial in tailoring effective and individualized treatment approaches for this population.

  • Open Access

    The effect of antifungal treatments on bronchoalveolar lavage galactomannan for the diagnosis of invasive fungal infections in patients with hematological malignancy: Single-center experience

    by Müge Yaşar, Fahir Özkalemkaş, Beyza Ener, Ezgi Demirdöğen, Münevver İrem Kök, Vildan Ozkocaman

    Background Invasive fungal infections (IFI) mainly caused by aspergillus species are one of the leading causes of death in patients undergoing immunosuppressive therapy for hematological malignancies. The presence of galactomannan in bronchoalveolar lavage fluid (BAL GM) is an important diagnostic marker. Some of the factors affecting the BAL GM are still unknown. Antifungal treatment administered before or after BAL also affect BAL GM results. Methods To investigate the effect of BAL GM timing on the diagnosis of IFE, 100 patients receiving immunosuppressive therapy with hematological malignancy at the Uludağ University Faculty of Medicine, Hematology Department, and underwent BAL over a 3-year period with the suspicion of IFE as well as 127 BAL procedures of these patients were examined. Results There were 70 patients who started antifungal therapy before BAL and 30 patients who did not. BAL GM was found positive in 33 (47.1%) of the 70 patients who received antifungal therapy compared to 22 (73.3%) of the 30 patients who did not receive antifungal therapy. There was a significant difference between the two groups in terms of BAL GM positivity (p = 0.016). Subsequently, 127 BAL procedures of these 100 patients were evaluated. When the second, third, and subsequent BAL procedures of the same patients were included in the study, BAL GM was positive in 41 (46.6%) of the 88 procedures in patients who received treatment before BAL and in 25 (64.1%) of the 39 procedures in patients who did not receive treatment before BAL. The rate of BAL GM positivity did not differ between groups (p = 0.068). Conclusions The balance between reducing the risk by initiating early antifungal therapy and maximizing the diagnostic value of BAL GM should be evaluated individually for each patient.

  • Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients

    by Zeynep Arzu Yegin, Emine Merve Savaş, Şeyma Yıldız, Münevver İrEm Kök, Meltem Büşra Erdemir, Başak Bostankolu Değirmenci, Zübeyde Nur Özkurt, Münci Yağcı

    Allogeneic hematopoietic stem cell transplantation (alloHCT) is associated with severe complications, most of which share a common physiopathological background characterized by endothelial dysfunction. A novel risk assessment model, endothelial activation and stress index (EASIX), has been introduced as a predictor of endothelial activation. This retrospective study was performed to evaluate the predictive impact of EASIX/modified-EASIX (mEASIX) on transplant outcome. Medical records of 398 alloHCT recipients [median age: 43(17–71) years; M/F: 243/155] were examined. EASIX/mEASIX were calculated at specific time points before and after transplantation. EASIX/mEASIX were significantly associated with transplant complications including engraftment syndrome, sinusoidal obstruction syndrome, febrile neutropenia and transplant associated thrombotic microangiopathy. The probability of overall survival was significantly higher in low-preconditioning mEASIX (day -7) group (37% vs 25.2%; p = 0.008; HR: 2.057; 95% CI: 1.208–3.504). The probabilities of day30 mortality (2.9% vs 19.4%; p = 0.017; HR: 7.028; 95% CI: 1.418–34.836), day100 mortality (9% vs 33%; p = 0.004; HR: 4.469; 95% CI: 1.619–12.336) and non relapse mortality (44.8% vs 61.4%; p = 0.005; HR: 2.551; 95% CI: 1.318–4.941) were lower in low-preconditioning mEASIX (day -7) group. This retrospective cohort analysis demonstrates the significant impact of EASIX/mEASIX on transplant complications and survival. Prospective analyses are mandatory to assess the predictive role of EASIX/mEASIX in clinical practice.


  • Open Access

    Polycystic Renal Disease Presented by Anuria and Nephrolithiasis Associated Progressive Kidney Damage: A Case Report

    by Müge Karacakayalilar, Selman Candan, Mehmet Çi̇çek, Abdülmecit Yildiz, Münevver İrem Kök

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disease. Kidney stones develop in 20-30% of patients with ADPKD.Hydronephrosis, which is the most valuable radiological finding in the diagnosis of stone-related postrenal insufficiency, may be difficult to differentiate from common cysts in ADPKD patients. When kidney dysfunction develops in ADPKD patients, Glomerular Filtration Rate (GFR) loss reaches an average of 4.4 to 5.9 mL / min per year. Faster deterioration in these patients requires investigation for prerenal factors such as dehydration that triggers acute kidney damage or stone-related postrenal factors. In ADPKD, stone-related postrenal obstruction should be considered in rapid GFR losses despite negative ultrasound report for hydronephrosis as there is frequent occurrence of kidney stones and the difficulty in detecting hydronephrosis with ultrasonography (US) in these patients. Here, we present a case with ADPKD whose renal functions rapidly deteriorated while under chronic follow-up and renal function markers returned to the basal levels with the treatment of the underlying cause.